FreeScore your brand plan before management does. Send me the scorecard
In short: a pharmaceutical pricing strategy starts from value, checks the competition and uses cost as a floor, never as the answer. For prescription medicines in Saudi Arabia and the GCC, the regulator sets and publishes the price, so the brand’s levers are the price it requests at registration, its tender strategy and its private-market terms. For OTC and consumer health products, where rules allow, the brand also shapes the shelf price, the price ladder across pack sizes, the margins along the chain and the balance between promotions and the everyday price. Every price decision ends in contribution margin, so test it there before you commit.
In more than twenty years of marketing medicines and consumer health brands in Egypt, Saudi Arabia and the GCC, I have seen more value lost through pricing than through almost any other lever. Not through one dramatic mistake, but through small ones repeated every year: a price requested from a cost sheet, a pack size added without a role, a promotion run because the quarter was short, a trade margin agreed without anyone checking what it did to the brand’s contribution.
Price is also the lever that marketers new to pharma most often dismiss. “The regulator sets the price, so there is nothing to do.” That is only half true. The list price of a registered medicine may be fixed, but the price you request, the evidence behind it, the pack sizes you register, the tender you bid on, the terms you give pharmacy chains and the promotions you run all remain decisions. For OTC and consumer health brands, many more levers are open.
This guide goes deeper than the price section of the pharmaceutical marketing mix guide, which explains where price sits among the seven Ps. Here the focus is on how to actually make pricing decisions: the approaches, the Saudi and GCC context, the OTC tools, the arithmetic of the margin chain and the research methods that help you choose. It is written for brand managers, product managers and marketing leads working on prescription (Rx), OTC and consumer health brands, and for marketers moving into pharma from other industries.
What Is a Pharmaceutical Pricing Strategy?
Short answer: it is the plan for what price a medicine or health product should carry, the case that justifies that price, and how the price is protected across the product’s life, inside the rules set by regulators, payers and tender bodies.
In most industries, pricing strategy means choosing a price that balances what customers will pay, what competitors charge and what the company needs to earn. Philip Kotler’s Marketing Management describes the standard sequence: set the pricing objective, estimate demand, estimate costs, analyse competitors’ prices and offers, choose a pricing method and then select the final price. That sequence still applies to medicines, but several steps work differently.
A pharmaceutical pricing strategy usually has four parts:
- The price itself: the price requested from the regulator for a registered medicine, or the shelf price for a product whose price the company and retailer can set.
- The value case: the clinical, economic and practical evidence that explains why the price is fair compared with the alternatives.
- The channel prices: what the distributor, the pharmacy, the hospital or the tender body pays, and the margins and terms at each step.
- The life-cycle plan: how the price will be defended or adjusted as competitors, generics and new indications arrive.
The strategy is not a separate document. It belongs inside the pharma brand plan, and it must follow from the positioning. A brand that claims to be the specialist’s choice for difficult cases cannot price itself like the cheapest option, and a brand built for broad access cannot carry a premium it has no evidence for. If the positioning is not settled, read the guide to pharma brand positioning before deciding the price.
What Are the Three Basic Pricing Approaches?
Short answer: cost-plus pricing (cost plus a margin), competitor or reference pricing (priced against comparable products or other countries) and value-based pricing (priced on the benefit delivered). Good pricing uses value to set the target, competitors to check it, and cost as the floor.
Cost-plus pricing
Cost-plus pricing takes the full cost of making and selling the product and adds a target margin. It is simple, easy to explain inside the company and easy to defend to a finance team. Its weakness is that it ignores the customer completely. The cost of making a tablet tells you nothing about what it is worth to the patient, the prescriber or the payer. Price too far above value and the product does not sell; price far below value and the company leaves money on the table that it needed to fund the next medicine.
Thomas Nagle and Georg Müller, in The Strategy and Tactics of Pricing, make the case against cost-driven pricing in detail: cost should decide whether a product is worth selling at the price the market will bear, not what that price should be. In pharma, cost-plus pricing still shows up in two places: in some tender bids, where the company works back from the lowest price it can accept, and in requests for price approval where a team has not built a value case and falls back on the cost sheet.
Competitor and reference pricing
Competitor pricing sets the price relative to similar products: at parity, at a premium or at a discount. Kotler calls a version of this going-rate pricing. It is the natural starting point for any product entering an existing category, and for OTC brands it is unavoidable, because the shopper sees the competing packs side by side.
In pharma, the word “reference” has a second, regulatory meaning. Many health authorities use external reference pricing: they look at the prices of the same medicine in a basket of other countries when setting or approving the local price. Some payers also use internal reference pricing: they group medicines they consider interchangeable and pay a common reimbursement amount for the group. Both mean that a price decision in one country can affect the price in another, which is why multinational companies plan launch sequences and prices across countries rather than one market at a time.
Value-based pricing
Value-based pricing sets the price according to the benefit the product delivers compared with the next best alternative. Nagle and Müller describe the logic as economic value: the price of the alternative plus the worth of whatever makes your product different, positive or negative. Hermann Simon, whose Confessions of the Pricing Man (2015) summarises decades of pricing consulting, makes the same point from another angle: price is the expression of value, and a company that cannot explain its value will end up competing on price alone.
For medicines, value is judged by several people at once. The prescriber values efficacy, safety and ease of use. The patient values convenience, tolerability and what they pay out of pocket. The payer values outcomes per unit of money spent. In countries with formal health technology assessment, such as England, where the National Institute for Health and Care Excellence assesses cost-effectiveness, that payer view becomes a structured review of clinical and economic evidence. Value-based pricing in pharma therefore means building the evidence that each of these judges needs.
| Approach | Starts from | Strength | Weakness | Where it fits in pharma |
|---|---|---|---|---|
| Cost-plus | Cost of goods and selling costs plus a target margin | Simple, easy to defend internally | Ignores customers and competitors; can leave value unclaimed or price the product out | A floor for tender bids and a check that a product is worth launching |
| Competitor / reference | Prices of comparable products, or of the same medicine in other countries | Grounded in the market the customer actually sees | Copies others’ mistakes; says nothing about your own differences | OTC shelf pricing, generics, and any market using external reference pricing |
| Value-based | Benefit delivered against the next best alternative | Links price to what the customer gains; supports a premium where it is earned | Needs evidence and research; harder to explain | Innovative Rx medicines, differentiated OTC and consumer health brands |
In practice, the three approaches are not alternatives but layers. Value tells you how high the price could go. Competitors and reference prices tell you where the market will compare you. Cost tells you how low you can go and still have a business. The price you choose sits somewhere between those markers, and the position you choose should match the brand’s strategy.
Why Is Pricing Medicines Different From Pricing Other Products?
Short answer: because the person who uses a medicine is often not the person who chooses it or pays for it, because many governments regulate medicine prices, because large volumes are bought through tenders, and because prices in one country are used as references in others.
Four features of the medicines market change the pricing problem.
Third-party payers. For many prescription medicines, the patient does not pay the full price. An insurer, an employer scheme, a government programme or a hospital pays most or all of it. That weakens the usual link between price and demand: a patient whose insurer pays is less sensitive to price, while the payer is very sensitive and has the power to refuse coverage. The pricing case has to be made to the payer as well as to the prescriber.
Regulated prices. Many countries set, approve or cap the prices of registered medicines. The company proposes a price with supporting information, and the authority decides. Prices may also be reviewed later, often downwards. In a regulated market, the commercial skill lies in the quality of the price request and in planning for reviews, not in moving the shelf price week by week.
Tenders. Hospitals and government health systems often buy through tenders, where suppliers bid against stated requirements. Price is usually a major criterion, but supply reliability, pack format, registration status and service can also count. A tender win can bring large volume at a low unit price; a tender loss can remove a product from a whole public system for the length of the contract.
Reference pricing and loss of exclusivity. External reference pricing links prices across countries, and the end of patent protection changes the price structure of a whole molecule. In the United States, the Hatch-Waxman Act of 1984 created the abbreviated approval route for generic medicines, and the price erosion that follows generic entry has shaped pricing strategy worldwide since. When generics arrive, the original brand must decide whether to hold its price and accept a smaller volume, follow prices down, or move part of its value into new formats or a switch to non-prescription status where the regulator allows it. How these phases unfold is covered in the guide to the pharmaceutical product life cycle.
How Are Prescription Medicine Prices Set in Saudi Arabia and the GCC?
Short answer: in Saudi Arabia, the SFDA sets and publishes the prices of registered medicines, and government buying goes through tenders run by NUPCO. The brand cannot simply choose its price, so its levers are the price it requests at registration, its tender strategy and the commercial terms it agrees in the private market.
For a prescription medicine in Saudi Arabia, the price is not a marketing decision in the usual sense. The Saudi Food and Drug Authority (SFDA) sets and publishes the price of each registered medicine, and that published price applies across the private market. The other GCC regulators also regulate medicine prices, with differences in method and detail, so a regional plan must check each market separately rather than assume one rule fits all.
I will not explain the SFDA’s price-setting method here, because the detail matters and changes over time. For a clear explanation of how the SFDA sets prices, see this guide to Saudi drug pricing from RaqibHealth, and always confirm the current rules with your regulatory team.
What a brand team can still decide falls into three areas.
The registered price request
The price is set once, at registration, and then lives with the product for years. The quality of the request matters: which pack sizes and strengths you register, the information you submit, how the product compares with what is already on the market, and how the request fits with prices in other countries where the product is sold. A pack size registered without thought becomes a fixed price point you cannot easily change later. Plan the registration portfolio and the price request together with regulatory affairs, well before the file is submitted. For the volume and pace of new registrations, see the Saudi drug registration statistics.
Tender strategy
Government hospitals in Saudi Arabia are supplied largely through centralised procurement, with NUPCO as the national procurement company. For many Rx brands, the tender is the single biggest pricing decision of the year. The questions are commercial ones: which tenders to bid on, at what price, with which pack formats, and what a win or a loss does to the brand’s presence in the private market. A very low tender price can win volume but also signals a value that private payers and prescribers may notice. A bid priced from cost alone may win business the company cannot supply profitably.
A sound tender strategy decides in advance which tenders are strategic (where presence matters for prescriber habits and patient continuity), which are volume plays and which are not worth bidding on, and sets a walk-away price for each based on contribution, not just on cost of goods.
Private-market terms
In the private market, the published price is the shelf price, but the company still negotiates terms with distributors, pharmacy chains, private hospitals and insurers: discounts where permitted, bonus stock, payment terms, rebates and service levels. These terms decide what the company actually earns per pack and how much the channel partner earns for supporting the brand. They are pricing decisions in everything but name, and they deserve the same discipline as the list price.
FreeScore your brand plan before management does. Send me the scorecard
How Much Pricing Freedom Do OTC and Consumer Health Brands Have?
Short answer: it depends on how the product is registered. OTC medicines may also have regulated prices, so check the current rules for your product. Products registered as supplements, cosmetics or other non-medicine categories usually have more freedom, and that is where the full set of consumer pricing tools comes into play.
The line between “regulated” and “free” does not fall neatly between Rx and OTC. A registered OTC medicine can sit under regulated pricing just like a prescription medicine, depending on the country and the category. In Saudi Arabia, check the current SFDA rules for the specific product with your regulatory team before you plan any price change or promotion. Products registered as supplements, cosmetics or general health products usually have more room, but they too can be affected by rules on promotions, claims and consumer protection.
Where prices are regulated, the levers described below still exist, but they move to the registration stage: the pack sizes you register, the price you request for each, and the permitted promotional mechanics. Where prices are free, the company and the retailer set them together, and the levers are used continuously.
Either way, OTC pricing has one feature Rx pricing lacks: the shopper sees the price and compares it on the shelf or on screen, often next to the pharmacist’s alternative suggestion. The rest of this guide focuses on that world. For how the pharmacy channel in Saudi Arabia is structured, see the Saudi pharmacy market statistics, and for how pricing fits into a launch, see the guide to an OTC product launch in Saudi Arabia.
How Do You Build a Price Ladder Across Pack Sizes?
Short answer: give every pack size a job (trial, everyday use, value for loyal users), make the price per unit fall as the pack grows so the larger pack is the logical choice for regular users, and keep the steps large enough that the packs do not compete with each other.
A price ladder, sometimes called pack-price architecture, is the set of price points a brand offers across its pack sizes and variants. It answers a simple question: which pack should each type of shopper buy, and does the price make that choice obvious?
A typical OTC ladder has three rungs:
- Entry pack: a small pack at a low absolute price, designed for first-time buyers and for the pharmacist recommending a product the shopper has never tried. Its price per unit is the highest on the ladder.
- Core pack: the pack most regular users should buy, sized for a typical course of use.
- Value pack: a large pack for loyal or chronic users, with the lowest price per unit, which rewards loyalty and raises the cost of switching to a competitor.
The example below is fictional and used only to illustrate the method. The prices are not benchmarks.
| Fictional Brand A pack | Sachets | Shelf price (SAR) | Price per sachet (SAR) | Job of the pack |
|---|---|---|---|---|
| Entry | 10 | 22.00 | 2.20 | Trial and first recommendation |
| Core | 20 | 40.00 | 2.00 | Regular use |
| Value | 40 | 72.00 | 1.80 | Loyal users |
Check the arithmetic: 22.00 divided by 10 is 2.20, 40.00 divided by 20 is 2.00, and 72.00 divided by 40 is 1.80. Each step up the ladder lowers the price per sachet by 0.20, so a regular user has a clear reason to move up, while the entry pack stays affordable for trial.
Three rules keep a ladder healthy. First, the price per unit must fall as the pack grows; a large pack that costs more per unit than the small one confuses shoppers and invites complaints. Second, the gaps must be wide enough that each pack has a distinct buyer; two packs with nearly the same price and size simply split the same shoppers and double the stock-keeping cost. Third, the number of rungs should match the shelf space the brand can realistically win. A ladder of five packs is worthless if pharmacies only list two.
Why Should You Compare Price per Day of Treatment?
Short answer: because shoppers and pharmacists compare pack prices, but the real cost of a treatment depends on the dose and the number of days in the pack. A pack that looks more expensive on the shelf can be the cheaper treatment.
Price per day of treatment divides the pack price by the number of days the pack lasts at the recommended dose. It is the fairest way to compare products with different pack sizes and dosing, and it is one of the most useful numbers to give pharmacists, who are often asked “which one is cheaper?”
Fictional example, for illustration only.
| Product | Pack | Dose | Days per pack | Shelf price (SAR) | Price per day (SAR) |
|---|---|---|---|---|---|
| Fictional Brand B | 30 tablets | 1 tablet a day | 30 | 45.00 | 1.50 |
| Fictional Brand C | 20 tablets | 2 tablets a day | 10 | 36.00 | 3.60 |
Brand C looks cheaper on the shelf (36.00 against 45.00), but its pack lasts 10 days (20 tablets at 2 a day) while Brand B’s lasts 30 days (30 tablets at 1 a day). Per day, Brand B costs 45.00 divided by 30, which is 1.50, and Brand C costs 36.00 divided by 10, which is 3.60. Brand C is 2.4 times as expensive per day of treatment.
If your brand wins on price per day but loses on shelf price, this is the number to put in pharmacist education materials, within what your approved claims allow. If your brand loses on price per day, you need a reason other than price for choosing it, and you should expect pharmacists to notice.
Do Psychological Price Points Work for Health Products?
Short answer: where prices are free, yes, within limits. Shoppers notice the first digit of a price more than the rest, and round thresholds act as mental barriers. For medicines with regulated prices, the price point is set at registration, so the thinking has to happen before the request is submitted.
Psychological pricing covers the ways shoppers read prices that are not strictly rational. The best documented is the left-digit effect: Manoj Thomas and Vicki Morwitz showed in a 2005 paper in the Journal of Consumer Research that people judge a price ending in 99 as noticeably lower than the next round number when the left digit changes, for example 2.99 against 3.00, but not when it does not, for example 2.59 against 2.60.
For OTC and consumer health brands with free pricing, three practical points follow:
- Know the thresholds in your category. If most competing packs sit just under a round number, a price just above it will feel like a different price band, even if the difference is small.
- Do not let a price increase cross a threshold carelessly. An increase that moves a pack from just under a round number to just over it can cost more volume than a larger increase that stays within the band.
- Do not over-apply it to health. For some products, especially premium dermo-cosmetics and products where trust matters, a round, confident price can signal quality better than a “bargain” ending. Test rather than assume.
Psychological price points are a fine-tuning tool. They will not save a price that is wrong for the value the brand delivers.
How Does the Margin Chain From Shelf Price to Distributor Work?
Short answer: start from the price the shopper pays, take off the pharmacy’s margin to get the pharmacy’s buying price, then take off the distributor’s margin to get the price the manufacturer receives. Every percentage in the chain is worked on the selling price at that step, unless the agreement says otherwise.
A pack that sells for 40 riyals on the shelf does not earn the manufacturer 40 riyals. Each partner in the chain takes a share for the work it does: the pharmacy for stocking, displaying, advising and selling; the distributor for importing or warehousing, delivering, extending credit and collecting payment. Brand managers who do not know their own margin chain cannot judge a trade deal, a price increase or a promotion.
Fictional example, for illustration only. The margins below are not benchmarks for any market; real margins depend on the product category, the regulations and the agreements in place. Taxes are left out to keep the arithmetic clear.
| Step | Calculation | Price per pack (SAR) |
|---|---|---|
| Consumer price (shelf) | Starting point | 40.00 |
| Pharmacy margin, 25% of its selling price | 40.00 × 25% = 10.00 | Pharmacy buys at 40.00 − 10.00 = 30.00 |
| Distributor margin, 10% of its selling price | 30.00 × 10% = 3.00 | Distributor buys at 30.00 − 3.00 = 27.00 |
| Manufacturer net price | What the brand receives | 27.00 |
So in this fictional chain, the manufacturer receives 27.00 of every 40.00 the shopper pays, which is 67.5 percent (27 divided by 40). The pharmacy earns 10.00 and the distributor 3.00, and 27.00 plus 10.00 plus 3.00 adds back to 40.00.
Margin is not markup. The pharmacy’s 10.00 is 25 percent of its selling price (10 divided by 40) but 33.3 percent of its buying price (10 divided by 30). The distributor’s 3.00 is 10 percent of its selling price (3 divided by 30) but 11.1 percent of its buying price (3 divided by 27). When a chain asks for “five more points”, the first question is: points of margin or points of markup? The answer changes the cost to the brand.
You can run your own chain, forwards from the manufacturer price or backwards from the shelf price, with the pharmacy trade margin calculator.
Two uses of the margin chain matter most. First, when you plan a shelf price for a product with free pricing, work backwards: decide the shelf price the shopper should see, deduct the channel margins, and check that the net price still leaves a healthy contribution. If it does not, the problem is the product cost or the positioning, not the trade. Second, when a chain asks for better terms, translate the request into riyals per pack and into contribution per pack before you answer.
Should You Run Promotions or Hold the Everyday Price?
Short answer: hold the everyday price as the default and use promotions for a specific job, such as trial, a seasonal peak or a new listing. Promotions that run all year become the real price, train shoppers to wait for the deal and cost contribution on every pack, including the ones that would have sold anyway.
In consumer goods, the choice between a stable everyday price and frequent promotions (often called high-low pricing) is one of the oldest debates in retail. For health brands, the balance tips towards the everyday price for three reasons.
- Trust. Medicines and health products sell on trust. A brand that is always on discount starts to look like a commodity, and shoppers may wonder what the “real” price is.
- Need-driven demand. Much OTC demand comes when the symptom appears. A discount rarely creates a headache; it mostly moves a sale that would have happened anyway, or pulls it forward into the pantry.
- Rules. Where prices are regulated, price cuts may not be allowed at all, and permitted mechanics (bundles, extra quantity, gift with purchase) must be checked with the regulatory team.
Promotions still have good jobs to do. A trial offer can bring new users to a brand with high repeat. A seasonal mechanic can win display space in the cold and flu season. A listing deal can secure a place in a new chain. The test is whether the promotion has a clear objective, a defined period and a measure of success, and whether the extra volume it needs is realistic, which the next sections show how to check.
How Do You Research the Right Price?
Short answer: use the Van Westendorp price sensitivity meter for a quick acceptable price range, the Gabor-Granger method to estimate demand at specific price points, and conjoint analysis to measure what shoppers will trade off between price and other features. Each has limits, so combine research with market data.
Price research matters most for OTC and consumer health products with free pricing, for new products entering a category, and for the price request of a new registered product where you need evidence about perceived value. Three methods cover most needs.
Van Westendorp price sensitivity meter
Published by the Dutch economist Peter van Westendorp in 1976, the price sensitivity meter asks respondents four questions about a product:
- At what price would it be so cheap that you would doubt its quality?
- At what price would it be a bargain, a great buy for the money?
- At what price would it start to seem expensive, though you would still consider it?
- At what price would it be so expensive that you would not consider buying it?
The answers are plotted as cumulative curves across price. Where the curves cross, they mark a range of acceptable prices, bounded by a point of marginal cheapness and a point of marginal expensiveness, with an optimal price point and an indifference point inside it. The method is quick and cheap, and it is good at revealing the price below which a health product starts to look untrustworthy. Its limits are that it records what people say rather than what they do, it does not show competing products, and it gives a range, not a demand curve.
Gabor-Granger method
Developed by the economists André Gabor and Clive Granger in the 1960s, this method asks respondents whether they would buy the product at a given price, then repeats the question at higher or lower prices. The share willing to buy at each price forms a simple demand curve, and multiplying each price by its share of buyers shows which price gives the most revenue. It is direct and easy to explain to a management team. Like Van Westendorp, it measures stated intent without competitors on the table, so it tends to overstate how many people would really buy.
Conjoint analysis
Conjoint analysis shows respondents a series of product profiles that combine different features, such as pack size, format, brand, claim and price, and asks them to choose between them. Statistical analysis of the choices estimates how much each feature, including price, contributes to the decision. Paul Green and V. Srinivasan’s 1978 review in the Journal of Consumer Research helped establish the method in consumer research. Choice-based conjoint is the most realistic of the three approaches, because it forces trade-offs and can include competitor profiles, and it can estimate how much more shoppers would pay for a feature. It is also the most expensive and needs a specialist to design and analyse.
| Method | What it tells you | Best used for | Main limit |
|---|---|---|---|
| Van Westendorp (1976) | A range of acceptable prices and the point where the product looks too cheap | Early checks for a new OTC or consumer health product | Stated views; no competitors; no demand curve |
| Gabor-Granger | Purchase intent at specific prices and the revenue-maximising price among them | Choosing between a few candidate price points | Stated intent tends to overstate real buying |
| Conjoint analysis | The trade-offs between price and other features, including willingness to pay | Pack and range decisions, premium features, competitive pricing | Cost, time and specialist design |
None of these replaces market evidence. Where you have sales data from past price changes, promotions or similar products, use it alongside the research. Where the decision is large, test the price in a limited set of outlets before rolling it out. And research the right people: for OTC products, ask pharmacists too, because their view of a fair price shapes what they recommend. Mapping where price enters the decision along the patient journey tells you whose price perception to research first.
How Does Price Affect Contribution Margin?
Short answer: every riyal taken off the net price comes straight off the contribution per pack, while costs stay the same. That is why a price cut needs a much larger rise in volume than the cut itself to keep total contribution flat, and why a small price increase can matter more to profit than a large volume gain.
Contribution margin is what each pack leaves after the costs that rise and fall with volume: cost of goods, freight, variable trade costs and similar items. It is the money that pays for marketing, the sales team, overheads and profit. Price decisions should always be tested at this level, not at the level of revenue.
Fictional example, for illustration only, continuing the margin chain above.
Brand A’s manufacturer net price is 27.00 per pack. Cost of goods is 9.00 and other variable costs are 2.00, so the contribution per pack is 27.00 minus 9.00 minus 2.00, which is 16.00, or about 59.3 percent of the net price (16 divided by 27). At 10,000 packs a month, total contribution is 10,000 times 16.00, which is 160,000.
Now the team proposes a promotion funded by the brand that reduces the net price by 4.00 per pack, a cut of about 14.8 percent (4 divided by 27). Costs do not change, so the contribution per pack falls from 16.00 to 12.00, a fall of 25 percent. To earn the same 160,000, the brand now needs 160,000 divided by 12.00, which is about 13,333 packs. That is a volume increase of 33.3 percent, more than double the 14.8 percent price cut.
| Fictional Brand A, per month | Before the promotion | During the promotion |
|---|---|---|
| Net price per pack (SAR) | 27.00 | 23.00 |
| Variable cost per pack (9.00 + 2.00) | 11.00 | 11.00 |
| Contribution per pack | 16.00 | 12.00 |
| Packs needed for 160,000 contribution | 10,000 | about 13,333 (+33.3%) |
The same logic works in reverse. If the net price could rise by 1.00 with no loss of volume, contribution per pack would rise from 16.00 to 17.00, an increase of 6.25 percent, which at 10,000 packs adds 10,000 to the month’s contribution. That is why pricing is so powerful, and why a promotion should be approved only when the team believes the volume it needs is realistic. To run these scenarios with your own numbers, use the consumer health contribution margin calculator, and track the result with the pharma marketing KPIs you already report.
How Should Pricing Differ by Segment and Market?
Short answer: price is part of the offer to a target segment, so it should follow segmentation and positioning decisions. Within a country, different channels and customer groups may see different net prices; across the GCC, each market has its own rules, so price each one deliberately.
Wendell Smith’s 1956 article in the Journal of Marketing set out market segmentation as a strategy, and price is one of the clearest ways a brand signals which segment it serves. A premium dermo-cosmetic, an everyday pain reliever and a value private label sit at different points on the price scale because they serve different shoppers with different needs. If you have not defined the segments, read the guide to segmentation and targeting in pharma first; it is hard to set a good price for a customer you have not chosen.
Across the GCC, a regional brand often wants one consistent price position, but the rules, channels and purchasing power differ by country. A regional plan should decide the intended position in each market (premium, parity or value against the local competitors), check each market’s price regulation, and then accept that the actual prices will differ. Before deciding where to enter and at what price, size the opportunity with the patient-based market sizing calculator, and fit the pricing plan into a wider go-to-market strategy.
What Are the Most Common Pharma Pricing Mistakes?
Short answer: pricing from cost alone, matching the market leader without a reason, discounting to fix a distribution problem, treating a regulated price as the end of pricing work, and confusing margin with markup in trade negotiations.
- Pricing from cost alone. A cost-plus price ignores what the product is worth to the people who choose and pay for it. It either leaves value unclaimed or prices the product above what the market will accept. Use cost as the floor and build the case from value.
- Matching the leader without a reason. Parity with the market leader feels safe, but it only makes sense if your brand offers the same value. A challenger with less awareness and fewer recommendations usually needs a reason to be chosen at the same price; a brand with a real advantage may be giving it away at parity.
- Discounting to fix a distribution problem. If a brand is not on the shelf, not visible or not recommended, a lower price does not help the shoppers who never see it. Check listings, stock, shelf position and pharmacist recommendation before you touch the price.
- Treating a regulated price as the end of the work.The registered price request, the pack sizes, tender strategy and private-market terms remain open. Teams that stop thinking about price once it is approved leave the most important decisions to chance.
- Adding pack sizes without a role. Each new pack is another fixed price point, another stock item and another listing to win. A ladder with overlapping rungs splits the same buyers and adds cost.
- Confusing margin with markup. Agreeing to a “percentage” without knowing whether it is on the buying or the selling price can change the cost of a trade deal substantially.
- Promotions without an exit. A promotion that never ends becomes the new price. Set an objective, a period and the volume needed to pay back before it starts.
- Ignoring the pharmacist’s view of value. For OTC products, the pharmacist often frames the price for the shopper. A price the pharmacist sees as unfair is a recommendation lost.
Key Takeaways
- Use value to set the target price, competitors and reference prices to check it, and cost as the floor
- Medicines are priced differently because of third-party payers, regulated prices, tenders and reference pricing
- In Saudi Arabia, the SFDA sets and publishes the prices of registered medicines and NUPCO runs government procurement, so Rx levers are the price request, tenders and private-market terms
- OTC medicines may also have regulated prices; check the current rules for each product
- Where prices are free, build a price ladder where each pack has a job and the price per unit falls as the pack grows
- Compare price per day of treatment, not just pack price, and know your margin chain from shelf to manufacturer
- Test every price change and promotion at contribution level before you commit
Frequently Asked Questions
What is a pharmaceutical pricing strategy?
A pharmaceutical pricing strategy is the set of decisions a company makes about the price of a medicine or health product, the evidence that supports it, and how that price is defended over the product's life. For prescription medicines it is mostly about the price requested from the regulator, tender strategy and private-market terms. For OTC and consumer health products, where rules allow, it also covers the shelf price, the price ladder across pack sizes, promotions and the margins along the chain.
What are the main pricing approaches in pharma?
There are three: cost-plus pricing, which adds a margin to the cost of making and selling the product; competitor or reference pricing, which sets the price against comparable products or prices in other countries; and value-based pricing, which sets the price according to the value the product delivers to patients, prescribers and payers. In practice, most medicines are priced with a mix of the three, inside the limits set by regulators and payers.
What is value-based pricing in pharma?
Value-based pricing sets the price according to the benefit a medicine delivers compared with the alternatives, such as better outcomes, fewer side effects, easier dosing or lower total treatment cost. In markets with health technology assessment, payers judge that value formally, often in terms of cost-effectiveness. For a brand team it means building the evidence and the economic case that justify the price, rather than starting from cost.
Who sets medicine prices in Saudi Arabia?
In Saudi Arabia, the prices of registered medicines are set and published by the Saudi Food and Drug Authority (SFDA). Government purchasing of medicines runs through tenders, with NUPCO as the national procurement company. A company therefore works through the price it requests at registration, its tender strategy and the commercial terms it agrees in the private market, rather than by setting its own shelf price for a registered medicine.
Are OTC medicine prices regulated in Saudi Arabia?
OTC medicines can also fall under regulated pricing, depending on how the product is registered. Products registered as supplements, cosmetics or other non-medicine categories usually have more freedom. Rules change and differ by category, so check the current SFDA rules for your specific product with your regulatory team before planning any price change or promotion.
What is the Van Westendorp price sensitivity meter?
It is a survey method published by the Dutch economist Peter van Westendorp in 1976. Respondents answer four questions about the price at which a product would be too cheap to trust, a bargain, getting expensive, and too expensive to consider. Plotting the answers gives a range of acceptable prices. It is quick and useful for OTC and consumer health products, but it measures stated views without competitor context, so treat the result as a range to test, not a final answer.
What is the difference between margin and markup in pharmacy pricing?
Margin is profit as a share of the selling price; markup is profit as a share of the buying price. A pharmacy that buys a pack for 30 and sells it for 40 makes 10, which is a 25 percent margin on the selling price but a 33.3 percent markup on the buying price. Mixing the two is one of the most common errors in trade negotiations.
Should an OTC brand cut its price to grow sales?
Only after checking two things. First, whether price is really the barrier: many brands discount to fix a problem that is actually distribution, shelf visibility or pharmacist recommendation. Second, how much extra volume the cut needs to keep the same contribution. Because a price cut comes straight off the contribution per pack, the volume increase needed is often far larger than the price cut itself.
What to Do Next
Take one brand you manage and write three numbers on a single page: its price per day of treatment against its two closest competitors, its full margin chain from shelf price to manufacturer net price, and its contribution per pack. If any of the three surprises you, that is where your next pricing decision should start. For a Rx brand, add a fourth line: the tenders you will bid on next year and the walk-away price for each.
If you are new to the field, start with Pharma marketing 101 for the basics, then read the guide to pharma marketing strategy to see where pricing fits among the other strategic choices.
